Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 07h00 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor
19 déc. 2022 07h00 HE
|
Revolution Medicines, Inc.
Findings Published in the Journal of Medicinal Chemistry Demonstrate Compound’s Exceptional Selectivity for mTORC1 over mTORC2 Tumor Regressions Observed During Combination Treatment with a Bi-Steric...
Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
07 déc. 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines to Participate in Upcoming Investor Conferences
09 nov. 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
07 nov. 2022 16h05 HE
|
Revolution Medicines, Inc.
Dose escalation ongoing in Phase 1/1b trials evaluating two RAS(ON) Inhibitor drug candidates, RMC-6236 (RASMULTI inhibitor) and RMC-6291 (KRASG12C inhibitor) Completed successful equity financing to...
Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
01 nov. 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor
22 sept. 2022 07h00 HE
|
Revolution Medicines, Inc.
KRASG12C(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRASG12C mutation RMC-6291 is first mutant-selective RAS(ON) Inhibitor to...
Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
01 sept. 2022 16h05 HE
|
Revolution Medicines, Inc.
Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel Daniel Simon to Join Company as Chief Business Officer REDWOOD CITY, Calif., Sept. 01, 2022 (GLOBE...
Revolution Medicines to Participate in Upcoming Investor Conferences
31 août 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
09 août 2022 16h02 HE
|
Revolution Medicines, Inc.
First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports development of portfolio of targeted drug candidates for RAS-addicted cancers ...